Due to the absence of vasoconstrictive effects, they are drugs with a lower cardiovascular risk than triptans (contraindicated in patients with, among others, coronary artery disease), however, it should be noted that blocking CGRP or its receptor with gepants/CGRP monoclonal antibodies may worsen ischaemia and related conditions such as hypertension. The gene discussed is CALCA; the disease is coronary artery disorder.